ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$17.66 USD
+0.46 (2.67%)
Updated Nov 8, 2024 04:00 PM ET
Pre-Market: $17.80 +0.14 (0.79%) 8:38 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.66 USD
+0.46 (2.67%)
Updated Nov 8, 2024 04:00 PM ET
Pre-Market: $17.80 +0.14 (0.79%) 8:38 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.
Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.
Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.
InMode (INMD) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.
Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.
Labcorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.
IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.
Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.
Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale
by Zacks Equity Research
Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.
Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B
by Zacks Equity Research
Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
by Zacks Equity Research
Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
by Zacks Equity Research
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
by Zacks Equity Research
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering
by Zacks Equity Research
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
by Zacks Equity Research
Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI